Recolony receives CHF 150,000 from Venture Kick
Bacteria-based cancer therapy
Revolutionary cancer immunotherapy
Subscribe to our Mailing List
Insights into Recolony
At Recolony, we focus our efforts in developing cancer therapies that primarily consist of selected commensal bacteria of the gut microbiota. These bacteria have an enormous influence on our immune system and are able to provoke and enhance an immune reaction against cancer. By harnessing the potential of beneficial gut microbiota, Recolony aims to develop a completely new class of drugs for the treatment and prevention of cancer.
Our aim is to shift the paradigm of cancer treatment away from single-target-drugs towards a gut microbiota guided activation of the immune system. Alterations of the gut microbiota with commensal bacteria have little or no side effects and have the potential to improve the quality of life of cancer patients under treatment considerably. We envision the future of cancer therapies and prevention to be based on, or supported by commensal microbiota or microbial-derived products and strive for maximizing the patients’ benefits in terms of efficacy and safety.
The science behind the therapy
High-class research for new, innovative therapies
Based on data from patients with colorectal cancer, we identified specific strains of bacteria that are less abundant in the gut microbiota of colorectal cancer patients compared to healthy individuals. Applying these bacteria in various models of solid tumors, including colorectal cancer, we found that the bacterial treatment activates immune cells, enabling them to infiltrate and kill malignant tumors.
Support and Awards
Anti-tumour efficacy, minimal side-effects and simple administration. These ingredients promise to establish Recolony as innovative breakthrough therapy.
Dr. Daniel Vasella / Recolony Advisory Board Member
Former CEO and Chairman of Novartis AG